RACGAP1 defines a malignant proliferative niche and represents a therapeutic vulnerability in lung adenocarcinoma

Key Points

• RACGAP1 serves as a promising prognostic biomarker in lung adenocarcinoma, improving clinical outcomes.
• The findings support a causal role of RACGAP1 in coordinating survival signaling and tumor suppression.
• Employing novel adjuvant strategies targeting RACGAP1 may enhance therapeutic effectiveness against lung cancer.
• Significant implications for future lung cancer therapies could arise from targeting this malignant proliferative niche.